(Q42217395)

English

Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors

scientific article published on 22 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Q Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

W Huang

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

H Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Y Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

J Zhao

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

A Song

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

H Xie

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

C Zhao

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

D Gao

9

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Y Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

publication date

22 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

732-738

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Gene therapy using adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Evaluation of risks related to the use of adeno-associated virus-based vectors.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Assessing the potential for AAV vector genotoxicity in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Immune responses to AAV in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Clinical gene therapy using recombinant adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Establishment of an AAV reverse infection-based array

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Rapid assessment of adenovirus serum neutralizing antibody titer based on quantitative, morphometric evaluation of capsid binding and intracellular trafficking: population analysis of adenovirus capsid association with cells is predictive of adenovi

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Clades of Adeno-associated viruses are widely disseminated in human tissues.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Directed evolution of adeno-associated virus yields enhanced gene delivery vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Immune responses to adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization

1 reference

https://api.crossref.org/works/10.1038%2FGT.2014.47

21 January 2018

Identifiers

10.1038/GT.2014.47

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42217395&oldid=2205131324"